- Home
- RAND vs MAIA Comparison
RAND vs MAIA Comparison
Compare RAND & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAND | MAIA |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4M | 49.3M |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RAND | MAIA |
|---|---|---|
| Price | $12.15 | $1.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.3K | ★ 1.1M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 9.87% | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.05 | $0.87 |
| 52 Week High | $26.00 | $3.19 |
Technical Indicators
Market Signals| Indicator | RAND | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 59.64 | 36.42 |
| Support Level | $10.56 | $1.20 |
| Resistance Level | $12.50 | $1.69 |
| Average True Range (ATR) | 0.41 | 0.19 |
| MACD | 0.13 | -0.09 |
| Stochastic Oscillator | 93.29 | 10.19 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.